查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047079

骨癌治療市場－全球產業規模、佔有率、趨勢、機會與預測：按骨癌類型、治療方法、地區和競爭格局分類，2021-2031年

Bone Cancer Treatment Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Bone Cancer Type, By Treatment Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球骨癌治療市場預計將從 2025 年的 14.2 億美元大幅成長至 2031 年的 19.3 億美元，複合年成長率為 5.25%。

該市場涵蓋多種治療方法原發性惡性骨腫瘤和骨轉移瘤的方法，包括手術、化療和放射線治療等。推動市場成長的關鍵因素包括骨癌和伊文氏肉瘤等骨癌發病率的上升，以及標靶藥物遞送系統的不斷進步，這些進步帶來了臨床療效的改善。例如，美國癌症協會估計，到2025年，美國將新增約3,770例原發性骨骼和關節癌病例，凸顯了對有效醫療管理的持續需求。然而，由於長期複雜的治療方法帶來的沉重經濟負擔以及特藥的高成本，市場擴張常常面臨巨大的阻力。這種經濟負擔嚴重限制了開發中國家患者的治療機會，並給全球醫療預算帶來了相當大的壓力。此外，嚴格的新抗癌藥物核准法規結構也限制了市場成長，設置了市場准入壁壘，並可能延遲創新治療方法惠及病患。

市場概覽
預測期 2027-2031
市場規模：2025年 14.2億美元
市場規模：2031年 19.3億美元
複合年成長率：2026-2031年 5.25%
成長最快的細分市場 標靶治療
最大的市場 北美洲

市場促進因素

全球骨癌治療市場的主要驅動力是原發性和轉移性骨癌在全球範圍內日益成長的發病率，這推動了對有效治療方法的需求。隨著包括乳癌、攝護腺癌和肺癌在內的主要固體癌的全球發生率持續上升，骨轉移病例也隨之增加。這些次發性性骨惡性腫瘤通常需要複雜的治療策略，包括使用骨修飾劑和放射性藥物，這直接擴大了需要安寧療護或根治性治療的患者群體。例如，根據世界衛生組織（WHO）2024年2月發布的報告，2022年全球估計新增癌症病例2,000萬例，這意味著大量人口面臨繼發性骨轉移的風險。此外，美國國立衛生研究院（NIH）2025年1月的一項研究分析了CT掃描報告，發現前列腺癌患者的5年骨轉移發生率最高，達到52%，這凸顯了有效控制轉移瘤的緊迫性。同時，孤兒藥和其他新型療法的監管核准速度加快，也為市場帶來了利好。這簡化了先進治療方法的引進流程。監管機構擴大授予有前景的候選藥物特殊認定，有效地鼓勵製藥公司投資於高風險、高回報的腫瘤學研究，特別是針對骨癌等罕見疾病的研究。這種快速核准流程顯著縮短了研發週期，使患者能夠更早獲得創新的標靶治療和免疫療法。一個值得關注的例子是，根據《醫藥高管》雜誌報道，FDA授予葛蘭素史克（GSK）的GSK5764227突破性療法認定，預計將於2025年1月獲批，用於治療復發性或難治骨癌成人患者。這些監管里程碑不僅驗證了新的作用機制，也代表著骨癌治療正朝著更個人化和更​​有效的方向發展。

市場挑戰

長期治療方法和高度專業化的藥物帶來的巨大經濟負擔，是全球骨癌治療市場成長的一大障礙。這項經濟挑戰直接阻礙了市場擴張，造成先進治療方法的可近性與患者及醫療系統的經濟承受能力之間存在巨大差距。在許多地區，尤其是在醫療基礎設施低度開發的地區，包括手術、化療和尖端標靶治療在內的多方面治療費用高昂，限制了這些必要治療方法的廣泛應用。因此，相當一部分合格的患者由於經濟障礙而無法接受標準治療，這限制了市場滲透率，減少了製藥企業的潛在收入來源，並降低了治療總量。癌症治療領域的近期價格趨勢進一步加劇了這個經濟負擔，凸顯了問題的嚴重性。根據美國臨床腫瘤學會（ASCO）預測，2025年上市的新抗癌藥物的年價格通常會超過25萬美元。這種高昂的價格結構給公共和私人保險公司都帶來了巨大壓力，往往導致報銷政策限制嚴格，病患自付費用也難以承受。這種經濟現實限制了新藥的推廣擴充性，並最終透過縮小能夠負擔這些必需藥物的患者群體，減緩了整體市場的成長。

市場趨勢

全球骨癌治療市場正經歷快速轉型，人工智慧 (AI) 的應用旨在提高早期檢測率並最佳化手術方案。先進的 AI 演算法正被應用於 MRI 和 CT 影像分析，以前所未有的精確度顯著提高良惡性骨病變的鑑別能力，從而最佳化術前策略。這一趨勢直接滿足了關鍵的臨床需求，例如提高診斷敏感性和改善保肢治療效果，從而能夠制定更個人化和有效的治療方案。 2025 年 2 月發表於《BMC Cancer》的一項研究，重點關注人工智慧在檢測骨轉移瘤方面的準確性，結果表明深度學習模型具有顯著的有效性，在識別骨骼惡性腫瘤方面實現了 0.95 的曲線下面積(AUC)。同時，新型放射性配體療法的出現正在改變治療格局，這些療法能夠將高標靶性放射治療直接應用於骨轉移瘤。與傳統放射療法相比，這些創新藥物正擴大被納入聯合治療，以最大限度地減少對周圍健康組織的治療方法性損傷並提高患者的生存率。製藥公司尤其關注α放射性同位素，這種同位素已被證明是克服晚期癌症患者對標準療法抗藥性的一種有前景的手段。例如，2025年5月，拜耳公司發表了XOFIGO®（氯化鐳-223）治療轉移性去勢抗性前列腺癌的III期PEACE III試驗的新數據。數據顯示，與Enzalutamide單藥治療相比，鐳-223合併Enzalutamide可使骨轉移患者的死亡風險降低31%。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球骨癌治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 骨癌的類型（原發性骨癌、轉移性骨癌）
    • 治療方法（化療、分子標靶治療、放射線治療、手術等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美骨癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲骨癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區骨癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲骨癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美骨癌治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球骨癌治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Amgen Inc
  • Baxter Inc
  • Bayer AG
  • ZetaMet Technology
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Recordati Group
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17386

The Global Bone Cancer Treatment Market is projected to expand significantly, growing from USD 1.42 Billion in 2025 to USD 1.93 Billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 5.25%. This market encompasses various therapeutic interventions designed to manage both primary malignant bone tumors and skeletal metastases, utilizing approaches such as surgery, chemotherapy, and radiation therapy. The primary drivers for this growth include the increasing incidence of bone cancers like osteosarcoma and Ewing sarcoma, alongside continuous advancements in targeted drug delivery systems that lead to enhanced clinical outcomes. For instance, the American Cancer Society estimated approximately 3,770 new cases of primary bone and joint cancer would be diagnosed in the United States in 2025, highlighting an ongoing demand for effective medical management. Market expansion, however, often faces significant headwinds due to the substantial financial burden associated with prolonged and complex treatment regimens, as well as the high costs of specialized pharmacological agents. This economic strain severely limits patient access in developing economies and places considerable pressure on public healthcare budgets globally. Furthermore, the market's growth is constrained by stringent regulatory frameworks governing the approval process for new oncology medications, which can create barriers to market entry and consequently delay the availability of innovative therapeutic options to patients.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.42 Billion
Market Size 2031USD 1.93 Billion
CAGR 2026-20315.25%
Fastest Growing SegmentTargeted Therapy
Largest MarketNorth America

Market Driver

The Global Bone Cancer Treatment Market is primarily driven by the escalating worldwide prevalence of both primary and metastatic bone cancers, which in turn intensifies the demand for effective therapeutic solutions. As the global incidence of major solid tumors-including breast, prostate, and lung cancer-continues to rise, there is a corresponding increase in cases of skeletal metastases. These secondary bone malignancies often necessitate intricate management strategies involving bone-modifying agents and radiopharmaceuticals, thereby directly enlarging the patient pool requiring palliative and curative treatments. For example, the World Health Organization reported an estimated 20 million new cancer cases globally in 2022 as of February 2024, creating a vast population at risk for secondary bone involvement. Additionally, a January 2025 study by the National Institutes of Health, which analyzed CT reports, found that prostate cancer patients exhibited the highest five-year incidence rate of bone metastases at 52%, underscoring the urgent need for robust metastasis management. Simultaneously, the market benefits from accelerated regulatory approvals for orphan drugs and other novel therapeutics, which streamline the introduction of advanced treatments. Regulatory bodies are increasingly granting special designations to promising drug candidates, effectively incentivizing pharmaceutical companies to invest in high-risk, high-reward oncology research, particularly for rare conditions such as osteosarcoma. These expedited pathways significantly reduce development timelines, allowing for earlier patient access to innovative targeted therapies and immunotherapies. A notable example is GSK's GSK5764227, which received Breakthrough Therapy Designation from the FDA in January 2025 for treating adult patients with relapsed or refractory osteosarcoma, as reported by Pharmaceutical Executive. Such regulatory milestones not only validate novel mechanisms of action but also signify a broader shift towards more personalized and effective care options for individuals battling bone cancer.

Market Challenge

The substantial financial burden linked to extended treatment regimens and highly specialized pharmacologics represents a critical obstacle to the growth of the Global Bone Cancer Treatment Market. This economic challenge directly impedes market expansion by creating a significant gap between the availability of advanced therapeutic interventions and the financial capacity of patients or healthcare systems to access them. In many regions, particularly those with fragmented healthcare infrastructures, the exorbitant costs associated with multi-modal care-encompassing surgery, chemotherapy, and cutting-edge targeted therapies-restrict the widespread adoption of these essential treatments. Consequently, manufacturers face limited market penetration, as economic barriers prevent a considerable portion of the eligible patient population from receiving standard-of-care therapies, thereby capping potential revenue streams and reducing the overall volume of administered treatments. This fiscal strain is further exacerbated by recent pricing trends within the oncology sector, which underscore the severity of the issue. According to the American Society of Clinical Oncology, new cancer drugs launched in 2025 frequently commanded annual prices exceeding $250,000. Such elevated pricing structures place immense pressure on both public and private payers, often resulting in restrictive reimbursement policies or prohibitive out-of-pocket costs for patients. This economic reality restricts the scalability of new therapeutic launches and ultimately slows the overall financial trajectory of the market by limiting the addressable consumer base capable of affording these essential medications.

Market Trends

The Global Bone Cancer Treatment Market is undergoing a rapid transformation driven by the integration of artificial intelligence (AI) for enhanced early detection and optimized surgical planning. Advanced AI algorithms are now being deployed to analyze MRI and CT imaging with unprecedented precision, significantly improving the differentiation between benign and malignant bone lesions and thereby refining preoperative strategies. This trend directly addresses critical clinical demands for improved diagnostic sensitivity and better limb salvage outcomes, allowing for the development of more personalized and effective intervention plans. A study published in BMC Cancer in February 2025, focusing on 'Accuracy of artificial intelligence in detecting tumor bone metastases,' validated the substantial efficacy of deep learning models, which achieved a pooled Area Under the Curve (AUC) of 0.95 in identifying skeletal malignancies. Simultaneously, the therapeutic landscape is being reshaped by the emergence of novel radioligand therapies, which enable highly targeted delivery of radiation directly to bone metastases. These innovative agents minimize collateral damage to healthy surrounding tissues compared to conventional radiation methods and are increasingly being incorporated into combination regimens to boost patient survival rates. Pharmaceutical developers are particularly focusing on alpha-emitting isotopes, which hold promise in overcoming resistance to standard treatments in patients with advanced stages of the disease. For example, Bayer reported in May 2025 that new data on XOFIGO(R) (radium-223 dichloride) in metastatic castration-resistant prostate cancer from the Phase III PEACE III Trial demonstrated that combining Radium-223 with enzalutamide led to a 31% reduction in the risk of death for patients with bone metastases, compared to enzalutamide alone.

Key Market Players

  • Amgen Inc
  • Baxter Inc
  • Bayer AG
  • ZetaMet Technology
  • Johnson & Johnson
  • Novartis AG
  • Pfizer Inc.
  • Recordati Group
  • Takeda Pharmaceutical Company
  • Eli Lilly and Company
  • Spectrum Pharmaceuticals Inc

Report Scope

In this report, the Global Bone Cancer Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bone Cancer Treatment Market, By Bone Cancer Type

  • Primary Bone Cancer
  • Secondary Bone Cancer

Bone Cancer Treatment Market, By Treatment Type

  • Chemotherapy
  • Targeted Therapy
  • Radiation Therapy
  • Surgery
  • Others

Bone Cancer Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bone Cancer Treatment Market.

Available Customizations:

Global Bone Cancer Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bone Cancer Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Bone Cancer Type (Primary Bone Cancer, Secondary Bone Cancer)
    • 5.2.2. By Treatment Type (Chemotherapy, Targeted Therapy, Radiation Therapy, Surgery, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Bone Cancer Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Bone Cancer Type
    • 6.2.2. By Treatment Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bone Cancer Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Bone Cancer Type
        • 6.3.1.2.2. By Treatment Type
    • 6.3.2. Canada Bone Cancer Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Bone Cancer Type
        • 6.3.2.2.2. By Treatment Type
    • 6.3.3. Mexico Bone Cancer Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Bone Cancer Type
        • 6.3.3.2.2. By Treatment Type

7. Europe Bone Cancer Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Bone Cancer Type
    • 7.2.2. By Treatment Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bone Cancer Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Bone Cancer Type
        • 7.3.1.2.2. By Treatment Type
    • 7.3.2. France Bone Cancer Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Bone Cancer Type
        • 7.3.2.2.2. By Treatment Type
    • 7.3.3. United Kingdom Bone Cancer Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Bone Cancer Type
        • 7.3.3.2.2. By Treatment Type
    • 7.3.4. Italy Bone Cancer Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Bone Cancer Type
        • 7.3.4.2.2. By Treatment Type
    • 7.3.5. Spain Bone Cancer Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Bone Cancer Type
        • 7.3.5.2.2. By Treatment Type

8. Asia Pacific Bone Cancer Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Bone Cancer Type
    • 8.2.2. By Treatment Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bone Cancer Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Bone Cancer Type
        • 8.3.1.2.2. By Treatment Type
    • 8.3.2. India Bone Cancer Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Bone Cancer Type
        • 8.3.2.2.2. By Treatment Type
    • 8.3.3. Japan Bone Cancer Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Bone Cancer Type
        • 8.3.3.2.2. By Treatment Type
    • 8.3.4. South Korea Bone Cancer Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Bone Cancer Type
        • 8.3.4.2.2. By Treatment Type
    • 8.3.5. Australia Bone Cancer Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Bone Cancer Type
        • 8.3.5.2.2. By Treatment Type

9. Middle East & Africa Bone Cancer Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Bone Cancer Type
    • 9.2.2. By Treatment Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bone Cancer Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Bone Cancer Type
        • 9.3.1.2.2. By Treatment Type
    • 9.3.2. UAE Bone Cancer Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Bone Cancer Type
        • 9.3.2.2.2. By Treatment Type
    • 9.3.3. South Africa Bone Cancer Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Bone Cancer Type
        • 9.3.3.2.2. By Treatment Type

10. South America Bone Cancer Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Bone Cancer Type
    • 10.2.2. By Treatment Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bone Cancer Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Bone Cancer Type
        • 10.3.1.2.2. By Treatment Type
    • 10.3.2. Colombia Bone Cancer Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Bone Cancer Type
        • 10.3.2.2.2. By Treatment Type
    • 10.3.3. Argentina Bone Cancer Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Bone Cancer Type
        • 10.3.3.2.2. By Treatment Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bone Cancer Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Amgen Inc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Baxter Inc
  • 15.3. Bayer AG
  • 15.4. ZetaMet Technology
  • 15.5. Johnson & Johnson
  • 15.6. Novartis AG
  • 15.7. Pfizer Inc.
  • 15.8. Recordati Group
  • 15.9. Takeda Pharmaceutical Company
  • 15.10. Eli Lilly and Company
  • 15.11. Spectrum Pharmaceuticals Inc

16. Strategic Recommendations

17. About Us & Disclaimer